- Conditions
- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Interventions
- Ivosidenib 500mg, Placebo
- Drug
- Lead sponsor
- Servier Bio-Innovation LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 19 more
Location Directory
Clinical trials in Jacksonville, Florida
This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7622
Shown on this page
12
Current sort
Recently updated
Location scope
Jacksonville, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 61–72 of 7,622 matching trials in Jacksonville, FL.
Live ClinicalTrials.gov results.
Institutions in Jacksonville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 577
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
- Conditions
- Coronary Artery Disease
- Interventions
- aspirin plus clopidogrel, prasugrel or ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Plaque Psoriasis
- Interventions
- Envudeucitinib, Apremilast, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 49 more
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
- Interventions
- CLN-049
- Drug
- Lead sponsor
- Cullinan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 13 more
- Conditions
- Meningioma
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 17 more
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 480
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
- Conditions
- Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1026
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- ALKS 7290 Dose, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
- Interventions
- nab-sirolimus
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 159
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more
- Conditions
- Relapsed/Refractory Primary Central Nervous System Lymphoma
- Interventions
- Tirabrutinib, Rituximab, Temozolomide
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 19 more